Delving into the Latest Updates on ZHB114 with Synapse

Overview

Basic Info

Drug Type

Interleukins

Synonyms

QHRD114, ZHB C002, ZHB-C002

+ [2]

Target

IL-2R

Action

antagonists

Mechanism

IL-2R antagonists(Interleukin-2 receptor antagonists)

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid NeoplasmAdvanced cancer

Inactive Indication-

Originator Organization

Zonhon Biopharma Institute, Inc.

Active Organization

Changzhou Qianhong Biopharma Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要研究目的：评估注射用QHRD114在晚期实体瘤受试者中的安全性、耐受性，确定最大耐受剂量（MTD）。次要研究目的： (1) 评估注射用QHRD114在晚期实体瘤受试者中的药代动力学（PK）/药效动力学（PD）特征； (2) 评估注射用QHRD114在晚期实体瘤受试者中的免疫原性； (3) 评估注射用QHRD114在晚期实体瘤受试者中的初步抗肿瘤疗效。

[Translation]

Primary study objectives: To evaluate the safety and tolerability of QHRD114 for injection in subjects with advanced solid tumors and determine the maximum tolerated dose (MTD). Secondary study objectives: (1) To evaluate the pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of QHRD114 for injection in subjects with advanced solid tumors; (2) To evaluate the immunogenicity of QHRD114 for injection in subjects with advanced solid tumors; (3) To evaluate the preliminary anti-tumor efficacy of QHRD114 for injection in subjects with advanced solid tumors.

Start Date27 Oct 2025

Sponsor / Collaborator

Zonhon Biopharma Institute, Inc.

[+1]

100 Clinical Results associated with ZHB114

Login to view more data

100 Translational Medicine associated with ZHB114

Login to view more data

100 Patents (Medical) associated with ZHB114

Login to view more data

100 Deals associated with ZHB114

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	China	Changzhou Qianhong Biopharma Co., Ltd.	27 Oct 2025
Advanced cancer	IND Approval	China	Changzhou Qianhong Biopharma Co., Ltd.	20 Dec 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data